Semaglutide hypothesized to achieve **4.2 kg** weight loss, outperforming other GLP-1 RAs in **Type 2 Diabetes**.

Type 2 Diabetes (DM2) management often involves GLP-1 receptor agonists (aGLP1s) which enhance glucose-dependent insulin secretion, reduce glucagon, and suppress appetite. While various aGLP1s demonstrate efficacy in glycemic control and cardiovascular event reduction, their comparative real-world effectiveness, particularly for weight loss and quality of life, remains an area of interest. This study addresses the need for direct, post-authorization comparisons of aGLP1s, especially Semaglutide, to inform clinical practice regarding their differential impacts on weight, HbA1c, and patient-reported outcomes.

This post-authorization, multicenter, non-randomized, prospective observational study will recruit 360 patients with Type 2 Diabetes initiating aGLP1 treatment for the first time. Participants will be followed for 44 weeks across 10 primary care centers. The primary endpoint is weight loss with different aGLP1s, including Semaglutide. Secondary endpoints include HbA1c reduction, changes in quality of life via EuroQol-5D and SF-12 questionnaires, and drug safety. The study is powered to detect differences in weight loss with >90% statistical power.